New Antiepileptic Drugs
Blaise F. D. Bourgeois, MD
Arch Neurol. 1998;55:1181-1183.
The current developments in the availability of new antiepileptic drugs (AEDs) are unprecedented. After a period of many years during which no new AED became available, 5 new AEDs were introduced in the United States between 1993 and 1997, and 2 more are expected to be approved soon. These new drugs are a most welcome addition to the therapeutic options in the treatment of epilepsy, but they also create a dilemma for the clinician because their individual places and their optimal use in the treatment of various forms of epilepsy are yet to be determined. This review serves to summarize the main characteristics of the newer AEDs.
From the Washington University School of Medicine, St Louis, Mo. Dr Bourgeois is now with Harvard Medical School, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand et al.
Arch Gen Psychiatry 2000;57:270-276.
ABSTRACT
| FULL TEXT
New Drugs: Which Should Be Included in the Formulary?: Epilepsy: All New Drugs Should Be Included
Pierre-Louis
Arch Neurol 2000;57:272-273.
FULL TEXT
Therapeutic Serum Levels for New Antiepileptic Drugs
Haruda and Bourgeois
Arch Neurol 1999;56:1300-1300.
FULL TEXT
A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome
Sachdeo et al.
Neurology 1999;52:1882-1882.
ABSTRACT
| FULL TEXT
A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children
Elterman et al.
Neurology 1999;52:1338-1338.
ABSTRACT
| FULL TEXT
|
